NCT04319146

Brief Summary

The promoter propose a pilot study evaluating the feasability of robot-assisted radical prostatectomy on outpatient in patients with localized prostate cancer. This study will enrole a total of 20 patients over one center, followed for 1 month. The total study duration will be 15 months, including statistical analysis and publication.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable prostate-cancer

Timeline
Completed

Started Jan 2022

Typical duration for not_applicable prostate-cancer

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 17, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 24, 2020

Completed
1.8 years until next milestone

Study Start

First participant enrolled

January 25, 2022

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

December 4, 2025

Status Verified

November 1, 2025

Enrollment Period

3.9 years

First QC Date

March 17, 2020

Last Update Submit

November 27, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Absence of conventional hospitalization after robot-assisted radical prostatectomy

    24 hours following the intervention

Secondary Outcomes (7)

  • Outpatient failure defined by a Chung score of less than 9 who cannot be discharged or admitted to a conventional hospitalization.

    24 hours following the intervention

  • Mesure of the operation duration will be estimated in minutes and will be recorded with a stopwatch in the operating room

    The day of surgery

  • The complication rate is determined by the number of patients who had one or more complications in the first month following the operation. Complications will be graded according to the Clavien Dindo classification.

    within the month after surgery

  • The consultation rate in a doctor's office is set by the number of patients who consulted a general practitioner in the first month after the operation, declared by the patient during the control visite (at 1 month)

    one month after surgery

  • •Any form of admission for urological reasons judged by the investigator in relation to robot-assisted radical prostatectomy within one month after the operation is considered as early unscheduled re-hospitalisation.

    one month after surgery

  • +2 more secondary outcomes

Study Arms (1)

robot-assisted radical prostatectomy

OTHER

patient with a prostate cancer will be operated with a robot-assisted method. They will be supported on an outpatient basis

Procedure: robot-assisted radical prostatectomy

Interventions

robot-assisted radical prostatectomy as first-line treatment

robot-assisted radical prostatectomy

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men
  • Older than 18 years old, if\> 70 years old, then patient having had a favorable onco-geriatric consultation (Balducci 2 and life expectancy\> 10 years)
  • Patient with localized prostate cancer applying for radical prostatectomy treatment
  • Patient accepting outpatient surgery
  • Radical prostatectomy performed as first-line treatment
  • BMI \<35
  • ASA score \<3
  • Accompanying person available (taxi authorized) to ensure return home
  • Have quick access to a telephone line
  • Patient who signed their informed consent
  • Patient covered by social security or other health insurance

You may not qualify if:

  • History of major abdominal surgery
  • History of pelvic radiotherapy
  • History of major urogenital malformation
  • Sleep apnea syndrome
  • Taking the following drugs within 48 hours (Plavix®, anti-vitamin K / curative LMWH)
  • Contraindication to ambulatory medical care
  • Inability to understand and sign the informed consent and to complete the self-questionnaires
  • Vulnerable people

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de NICE Pasteur 2

Nice, CHU de Nice, 06000, France

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Open label, monocentric study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 17, 2020

First Posted

March 24, 2020

Study Start

January 25, 2022

Primary Completion

December 1, 2025

Study Completion

December 1, 2025

Last Updated

December 4, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

no plan description is necessary

Locations